Solid Biosciences Shares Jump 12% on Gene Therapy Approval Tailwind
Solid Biosciences shares rose 12.15% after FDA CBER director Dr. Vinay Prasad announced his April departure, which analysts say could ease approval for its gene therapy programs. His exit is seen as a regulatory tailwind for rare disease sponsors using single-arm studies and external controls to support filings.
1. Dr. Prasad to Leave CBER in April
FDA Center for Biologics Evaluation and Research director Dr. Vinay Prasad will step down in April after a tenure marked by controversial decisions, including blocking expedited review for uniQure’s AMT-130 and issuing a CRL for Regenxbio’s RGX-121 gene therapy.
2. SLDB Shares Rise 12.15%
Solid Biosciences shares climbed 12.15% to $7.57 following the resignation announcement, reflecting investor optimism that the company’s Duchenne muscular dystrophy gene therapy pipeline could benefit from a more accommodating regulatory environment.
3. Regulatory Implications for Gene Therapies
Analysts view Prasad’s departure as a tailwind for rare disease sponsors that rely on single-arm clinical studies and external control groups to demonstrate efficacy, potentially reducing the need for costly additional trials or repeat studies.
4. Broader Biotech Stock Reactions
Other biotech names also rallied, with uniQure and Regenxbio trading higher, Capricor Therapeutics up 9.07%, Crispr Therapeutics rising 2.80% and Sarepta Therapeutics gaining 4.31% as market participants priced in a shift toward softer review standards.